Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Researchers review best acyclovir dose for obese patients with rare brain infection

NCT ID NCT05127395

Knowledge-focused Sponsor: Methodist Health System Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study reviewed medical records of 50 obese adults with HSV encephalitis (a brain infection) to see how different ways of calculating acyclovir dose affect survival. Researchers looked at patients treated between 2013 and 2019 at six hospitals. The goal was to find the safest and most effective dosing method for this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

50 people

The number who actually took part.

Started

Mar 2021

Finished

Apr 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

* More than one dosing weight strategy utilized for \> 24 hours for IV acyclovir dosing during the index admission * Patients transferred to the hospital already on IV acyclovir for HSV encephalitis * ESRD on admission * Concomitant pathogen causing meningitis or encephalitis * Oral acyclovir used for treatment

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients Admitted to a SSM Health - St. Clare (STL), St. Mary's (STL), Saint Louis University Hospital (STL), St. Anthony's (OKC), St. Mary's Madison (WIS), Rush University Medical Center (RUMC), or Methodist Dallas Medical Center * \> 18 years old * Positive cerebrospinal fluid (CSF) PCR for HSV-1 or HSV-2 * BMI \> 30 kg/m2 * Received guideline-approved, weight-based doses of IV acyclovir for HSV encephalitis for at least 72 hours during the index admission * Received appropriately renal dose-adjusted doses of IV acyclovir per package insert recommendations Exclusion Criteria: * More than one dosing weight strategy utilized for \> 24 hours for IV acyclovir dosing during the index admission * Patients transferred to the hospital already on IV acyclovir for HSV encephalitis * ESRD on admission * Concomitant pathogen causing meningitis or encephalitis * Oral acyclovir used for treatment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HSV encephalitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

herpes simplex encephalitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HSV encephalitis

Contacts and locations

Locations

  • Methodist Charlton Medical Center

    Dallas, Texas, 75237, United States